SCHEMBL2335273

SCHEMBL2335273

COc1cc(CN(Cc2ccccn2)S(=O)(=O)c2ccc(Cl)cc2)ccc1OCCc1scnc1C

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.54
PDE4B Q07343 1/20 0.54
PDE4C Q08493 1/20 0.54
PDE4D Q08499 1/20 0.54
CXCR3 P49682 12/20 0.51
KCNA5 P22460 1/20 0.46
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
TAS2R14 Q9NYV8 1/20 0.43
MAPK1 P28482 1/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2339348 0.88 ALDH1A1 (0.43) ALDH1A1LMNATAS2R14TP53TSHR
SCHEMBL2337898 0.87 TAS2R14 (0.42) PDE4APDE4BPDE4CPDE4DCXCR3
SCHEMBL2341038 0.86 ALDH1A1 (0.40) CXCR3ALDH1A1LMNATAS2R14MAPK1
SCHEMBL2338966 0.85 MEN1 (0.42) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL2332019 0.85 HIF1A (0.45) ALDH1A1LMNATAS2R14TSHRHTT
SCHEMBL2337909 0.84 ALDH1A1 (0.44) ALDH1A1LMNATAS2R14TSHRHTT
SCHEMBL2338098 0.84 ALDH1A1 (0.40) CXCR3ALDH1A1LMNATAS2R14TSHR
SCHEMBL2335244 0.84 TP53 (0.44) CXCR3ALDH1A1LMNATAS2R14TP53
SCHEMBL2333362 0.84 HIF1A (0.46) ALDH1A1LMNATAS2R14TSHRHTT
SCHEMBL2334778 0.83 LMNA (0.41) ALDH1A1LMNATAS2R14TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
EP-1723102-A2 N-SUBSTITUTED BENZENE SULFONAMIDES Elan Pharmaceuticals, Inc. (US) 2006-11-22 EP claimed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US claimed
WO-2005090296-A2 N-SUBSTITUTED BENZENE SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2005-09-29 WO claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
EP-1723102-A2 N-SUBSTITUTED BENZENE SULFONAMIDES Elan Pharmaceuticals, Inc. (US) 2006-11-22 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed
WO-2005090296-A2 N-SUBSTITUTED BENZENE SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE PDE4A 2348/4885PDE4B 2397/4885PDE4C 2854/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE PDE4A 2348/4885PDE4B 2397/4885PDE4C 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.